Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

ADALTA LIMITED

INVESTOR PRESENTATION - ADALTA LIMITED

ASX:1AD

ADALTA LIMITED

Health Care

AdAlta is an innovative biotech company developing a unique range of new drug treatments. AdAlta has pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases. AdAlta is utilising the power of the i-body technology to create a pipeline of new drugs, with an initial focus on treating fibrotic diseases.

Read more

Market Cap

28.20m

Price at Close

$0.115

4w avg. Volume

1.55m

4w avg. Turnover

$214.76k

Announcements
announcementt+2 movementdate
  • AusBiotech presentation including Phase I status update

    Periodic Reports · Market sensitive

  • -

    26 Oct 2020

-

26 Oct 2020
  • Notice of Annual General Meeting/Proxy Form

    Notice Of Meeting

  • +3.70%

    21 Oct 2020

+3.70%

21 Oct 2020
  • Annual General Meeting - Letter to Shareholders

    Notice Of Meeting

  • +3.70%

    21 Oct 2020

+3.70%

21 Oct 2020
  • R&D Tax Incentive Refund received

    Periodic Reports · Market sensitive

  • +3.85%

    18 Oct 2020

+3.85%

18 Oct 2020
  • Quarterly Appendix 4C and Activities Report

    Commitments test entity quarterly reports · Market sensitive

  • -9.68%

    11 Oct 2020

-9.68%

11 Oct 2020
  • Investor Presentation - BIO investor forum

    Periodic Reports · Market sensitive

  • -12.90%

    09 Oct 2020

-12.90%

09 Oct 2020
  • Response to ASX Price Query

    ASX Query · Market sensitive

  • -12.90%

    09 Oct 2020

-12.90%

09 Oct 2020
  • Change in substantial holding

    Shareholder Details

  • +13.04%

    06 Oct 2020

+13.04%

06 Oct 2020
  • Broader role for CXCR4 in fibrosis

    Progress Report

  • +19.05%

    29 Sep 2020

+19.05%

29 Sep 2020
  • Adjustment to Option Exercise Prices

    Issued Capital

  • +10.00%

    24 Sep 2020

+10.00%

24 Sep 2020
Market Data

Current Price

$0.115

52WK HIGH

$0.185

52WK LOW

$0.04

1YR RETURN

-4.17%

1YR RETURN VS. SECTOR

-23.26%

90 DAY RETURN

-8.00%

ASX RANK

1,313

/2,015

SECTOR RANK

34

/47

SHARES OUTSTANDING

245.18m
ASX:1AD

ADALTA LIMITED

Health Care

AdAlta is an innovative biotech company developing a unique range of new drug treatments. AdAlta has pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases. AdAlta is utilising the power of the i-body technology to create a pipeline of new drugs, with an initial focus on treating fibrotic diseases.

Read more

Market Cap

28.20m

Price at Close

$0.115

4w avg. Volume

1.55m

4w avg. Turnover

$214.76k

ASX:1AD is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.